European Study of Cerebral Aspergillosis Treated With Isavuconazole (ESCAI)

Imagine Institute

Status: Completed

Conditions: Invasive Aspergillosis; Cerebral Aspergillosis

Study type: Observational

Funder types: Other

Identifiers

NCT04486885

hj-20-ESCAI

Details and patient eligibility

About

Study clinical context Cerebral aspergillosis (CA) is a rare location of invasive aspergillosis (IA), associated with a high morbidity and mortality. Since 2002, voriconazole is the recommended first line treatment of invasive aspergillosis. More recently, isavuconazole appeared to be not less effective than voriconazole in the treatment of filamentous IFI, with a better tolerance profile.

The investigators aim to evaluate better the efficacy and the safety of isavuconazole in the treatment of cerebral aspergillosis by a descriptive, multicentric, international retrospective cohort study.

Enrollment: 41 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Proven or probable cerebral aspergillosis according to the EORTC criteria modified by adding diabetes in the host criteria
• In child or adult
• Treated by isavuconazole at least 7 days
• Diagnosed between March 2017 and June 2020

Exclusion criteria

• Possible cerebral aspergillosis
• isavuconazole treatment for less than 7 days